Gilead Sciences (GILD)

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q3 2026 results exceeding the market’s revenue expectations, with sales up 6.8% year on year...

Base business sales surged 16%, marking strongest growth in over a decade.

Gilead Sciences (NASDAQ:GILD) reported third-quarter 2026 base business sales growth of 16% year over year, its strongest growth rate in more than a decade, as HIV products, TRODELVY and Livdelzi drove performance. The company also raised its full-year base business revenue outlook while outlining t

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) beat Wall Street’s revenue expectations in Q3 2026, with revenue up 6.8% year on year to $8.3 billion...

Gilead Sciences crushed Wall Street's sales expectations on the back of its HIV treatments and cancer drug Trodelvy.

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting results this Thursday after the bell. Here’s what you need to know. Gilead Sciences...

BBH offers lower costs and concentrated large-cap exposure, while PBE delivers higher dividend income and slightly better five-year returns through a multifactor strategy.

These two healthcare ETFs offer investors exposure to some of medicine's biggest names, but their different approaches to investing could lead to very different results.

Both of these biotech stocks could be appealing to income investors.

Here's how pharmaceutical stocks compare to biotech in terms of risk, rewards, and costs.

Both of these ETFs look the part, but only one is truly the better buy for investors.

Arcus Biosciences (NYSE:RCUS) presented updated clinical and translational data for casdatifan, its investigational HIF-2 alpha inhibitor, outlining development plans across first-line, second-line and later-line clear cell renal cell carcinoma (RCC). Chief Executive Officer Terry Rosen said the co

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to conv...

The company's recent momentum continues unabated.

Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements...

PJP's one-year return beats RSPH's, but RSPH offers broader diversification across 61 healthcare holdings at a lower expense ratio.

VanEck's lower 0.35% expense ratio appeals to cost-conscious investors, while First Trust's $2.9 billion in assets and equal-weighted approach offer broader diversification across 30 biotech holdings.

BBH concentrates on 25 large-cap biotech leaders, while XPH diversifies across 62 pharmaceutical holdings. Both charge 0.35% annually, but their five-year returns diverged significantly.

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Gilead Sciences (NASDAQ:GILD)...

Compugen (NASDAQ:CGEN) outlined the clinical rationale for its COM701 antibody in platinum-sensitive ovarian cancer and described an expansion of its AI-powered discovery platform into tumor-associated antigen, or TAA, research during a company update event. President and Chief Executive Officer Er